Rationale and Design of RESILIENCE: A Prospective Randomized Clinical Trial Evaluating Remote Ischaemic Conditioning for the Prevention of Anthracycline Cardiotoxicity
Study context
- Population
- Lymphoma patients scheduled for ≥5 anthracycline-containing chemotherapy cycles with ≥1 anthracycline cardiotoxicity (AC)-associated risk factor
- Planned comparison
- Remote ischaemic conditioning (RIC) vs sham
- Primary endpoint
- Absolute change from baseline in CMR-based LVEF
Methodological detailsdesign and rationale, multinational, prospective, phase II, double-blind, sham-controlled, cardiac magnetic resonance (CMR) at baseline, after the third cycle and 2 months after the end of chemotherapy; clinical follow-up over an anticipated median of ≥24 months, Main secondary outcome: AC events (left ventricular ejection fraction (LVEF) drop ≥10 absolute points, or ≥5 and <10 points to <50%)
- Design and rationale
- Multinational
- Prospective
- Phase II
- Double-blind
- Sham-controlled
- CMR at baseline, after the third cycle and 2 months after the end of chemotherapy; clinical follow-up over an anticipated median of ≥24 months
- Main secondary outcome: AC events (LVEF drop ≥10 absolute points, or ≥5 and <10 points to <50%)
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and Design of RESILIENCE: A Prospective Randomized Clinical Trial Evaluating Remote Ischaemic Conditioning for the Prevention of Anthracycline Cardiotoxicity. Eur J Heart Fail. Published 30 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →